Current Advances in Zika Vaccine Development
Zika virus (ZIKV), an emerging arthropod-borne flavivirus, was first isolated in Uganda in 1947 from monkeys and first detected in humans in Nigeria in 1952; it has been associated with a dramatic burden worldwide. Since then, interventions to reduce the burden of ZIKV infection have been mainly res...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/11/1816 |
| _version_ | 1797466329285918720 |
|---|---|
| author | Yuchen Wang Lin Ling Zilei Zhang Alejandro Marin-Lopez |
| author_facet | Yuchen Wang Lin Ling Zilei Zhang Alejandro Marin-Lopez |
| author_sort | Yuchen Wang |
| collection | DOAJ |
| description | Zika virus (ZIKV), an emerging arthropod-borne flavivirus, was first isolated in Uganda in 1947 from monkeys and first detected in humans in Nigeria in 1952; it has been associated with a dramatic burden worldwide. Since then, interventions to reduce the burden of ZIKV infection have been mainly restricted to mosquito control, which in the end proved to be insufficient by itself. Hence, the situation prompted scientists to increase research on antivirals and vaccines against the virus. These efforts are still ongoing as the pathogenesis and immune evasion mechanisms of ZIKV have not yet been fully elucidated. Understanding the viral disease mechanism will provide a better landscape to develop prophylactic and therapeutic strategies against ZIKV. Currently, no specific vaccines or drugs have been approved for ZIKV. However, some are undergoing clinical trials. Notably, different platforms have been evaluated for the design of vaccines, including DNA, mRNA, viral vectors, virus-like particles (VLPs), inactivated virus, live attenuated virus, peptide and protein-based vaccines, passive immunizations by using monoclonal antibodies (MAbs), and vaccines that target vector-derived antigens. These vaccines have been shown to induce specific humoral and cellular immune responses and reduce viremia and viral RNA titers, both in vitro and in vivo. This review provides a comprehensive summary of current advancements in the development of vaccines against Zika virus. |
| first_indexed | 2024-03-09T18:35:20Z |
| format | Article |
| id | doaj.art-8b10efc735de4c8e9d7fd2a70eaba69c |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T18:35:20Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-8b10efc735de4c8e9d7fd2a70eaba69c2023-11-24T07:13:09ZengMDPI AGVaccines2076-393X2022-10-011011181610.3390/vaccines10111816Current Advances in Zika Vaccine DevelopmentYuchen Wang0Lin Ling1Zilei Zhang2Alejandro Marin-Lopez3Department of Inspection and Quarantine Technology Communication, Shanghai Customs College, Shanghai 201204, ChinaDepartment of Inspection and Quarantine Technology Communication, Shanghai Customs College, Shanghai 201204, ChinaDepartment of Inspection and Quarantine Technology Communication, Shanghai Customs College, Shanghai 201204, ChinaSection of Infectious Diseases, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06420, USAZika virus (ZIKV), an emerging arthropod-borne flavivirus, was first isolated in Uganda in 1947 from monkeys and first detected in humans in Nigeria in 1952; it has been associated with a dramatic burden worldwide. Since then, interventions to reduce the burden of ZIKV infection have been mainly restricted to mosquito control, which in the end proved to be insufficient by itself. Hence, the situation prompted scientists to increase research on antivirals and vaccines against the virus. These efforts are still ongoing as the pathogenesis and immune evasion mechanisms of ZIKV have not yet been fully elucidated. Understanding the viral disease mechanism will provide a better landscape to develop prophylactic and therapeutic strategies against ZIKV. Currently, no specific vaccines or drugs have been approved for ZIKV. However, some are undergoing clinical trials. Notably, different platforms have been evaluated for the design of vaccines, including DNA, mRNA, viral vectors, virus-like particles (VLPs), inactivated virus, live attenuated virus, peptide and protein-based vaccines, passive immunizations by using monoclonal antibodies (MAbs), and vaccines that target vector-derived antigens. These vaccines have been shown to induce specific humoral and cellular immune responses and reduce viremia and viral RNA titers, both in vitro and in vivo. This review provides a comprehensive summary of current advancements in the development of vaccines against Zika virus.https://www.mdpi.com/2076-393X/10/11/1816Zika virusZika vaccinesDNA vaccinesmRNA vaccineslive attenuatedwhole inactivated |
| spellingShingle | Yuchen Wang Lin Ling Zilei Zhang Alejandro Marin-Lopez Current Advances in Zika Vaccine Development Vaccines Zika virus Zika vaccines DNA vaccines mRNA vaccines live attenuated whole inactivated |
| title | Current Advances in Zika Vaccine Development |
| title_full | Current Advances in Zika Vaccine Development |
| title_fullStr | Current Advances in Zika Vaccine Development |
| title_full_unstemmed | Current Advances in Zika Vaccine Development |
| title_short | Current Advances in Zika Vaccine Development |
| title_sort | current advances in zika vaccine development |
| topic | Zika virus Zika vaccines DNA vaccines mRNA vaccines live attenuated whole inactivated |
| url | https://www.mdpi.com/2076-393X/10/11/1816 |
| work_keys_str_mv | AT yuchenwang currentadvancesinzikavaccinedevelopment AT linling currentadvancesinzikavaccinedevelopment AT zileizhang currentadvancesinzikavaccinedevelopment AT alejandromarinlopez currentadvancesinzikavaccinedevelopment |